{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T05:01:50Z","timestamp":1747026110244},"reference-count":30,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2007,3,1]],"date-time":"2007-03-01T00:00:00Z","timestamp":1172707200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2007,3,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Clinical trials show that vardenafil produces effective and satisfactory first-dose success rates and reliability for erection and intercourse in men with erectile dysfunction (ED).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Aim<\/jats:title>\n                  <jats:p>This study was conducted to evaluate real-life efficacy, safety, and acceptance of vardenafil in men with ED.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This open-label, prospective study, conducted in 6,740 U.S. centers, included an initial visit and one or two follow-up visits within a 2-month period of the first vardenafil dose. Vardenafil was administered in 5\u201320 mg doses.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Main Outcome Measures<\/jats:title>\n                  <jats:p>Efficacy variables included first-dose success rates for vaginal penetration, maintenance of erection, and satisfaction based on physician and patient assessments. Safety was assessed by adverse events (AEs).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 30,010 men were included in the safety\/intent-to-treat (S\/ITT) analysis, with 26,043 men in the adjusted S\/ITT population. Vardenafil improved erectile function in 78% of men, with 75% rating overall efficacy as \u201csatisfying\u201d or \u201cvery satisfying.\u201d The overall rates of successful penetration and maintenance with vardenafil following the first dose were 78% and 68%, respectively. For men with mild and moderate ED, first-dose success rates for penetration were 89% and 82%, respectively, and for maintenance, 82% and 71%, respectively. First-dose penetration and maintenance of erection rates were 76% and 66%, respectively, for men with self-reported hypertension, and 70% and 60%, respectively, for men with diabetes mellitus. At study end, 67% of patients preferred to continue using vardenafil. The most frequently reported AEs were headache (4%) and flushing (2%). Vardenafil was well tolerated, with a \u201csatisfied\/very satisfied\u201d tolerability rating in 75% of cases as assessed by the physician.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>This observational study demonstrated the tolerability and efficacy of vardenafil in men with ED and comorbidities. Vardenafil provided a high rate of first-dose intercourse success and a favorable safety profile in patients with and without comorbid disease.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1111\/j.1743-6109.2006.00383.x","type":"journal-article","created":{"date-parts":[[2006,11,6]],"date-time":"2006-11-06T16:53:25Z","timestamp":1162832005000},"page":"432-439","source":"Crossref","is-referenced-by-count":28,"title":["Real-Life Safety and Efficacy of Vardenafil in the Treatment of Erectile Dysfunction\u2014Results from 30,010 U.S. Patients"],"prefix":"10.1093","volume":"4","author":[{"given":"Eric","family":"Cheng","sequence":"first","affiliation":[{"name":"Department of Family Medicine, State University of New York, Health Science Center , Brooklyn , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2007,3,1]]},"reference":[{"key":"2024032600473892200_bib1","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/S0022-5347(17)34871-1","article-title":"Impotence and its medical and psychosocial correlates: Results of the Massachusetts Male Aging Study","volume":"151","author":"Feldman","year":"1994","journal-title":"J Urol"},{"key":"2024032600473892200_bib2","first-page":"83","article-title":"NIH Consensus Conference. Impotence. NIH Consensus Development Panel on Impotence","volume-title":"JAMA","author":"NIH","year":"1993"},{"issue":"suppl 4","key":"2024032600473892200_bib3","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1038\/sj.ijir.3900567","article-title":"The worldwide prevalence and epidemiology of erectile dysfunction","volume":"12","author":"McKinlay","year":"2000","journal-title":"Int J Impot Res"},{"key":"2024032600473892200_bib4","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1097\/00006842-199807000-00011","article-title":"The relationship between depressive symptoms and male erectile dysfunction: Cross-sectional results from the Massachusetts Male Aging Study","volume":"60","author":"Araujo","year":"1998","journal-title":"Psychosom Med"},{"key":"2024032600473892200_bib5","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/BF01542116","article-title":"Changes in erectile responsiveness during androgen replacement therapy","volume":"12","author":"Bancroft","year":"1983","journal-title":"Arch Sex Behav"},{"issue":"6 Pt 1","key":"2024032600473892200_bib6","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1097\/01.ju.0000125198.32936.38","article-title":"The prevalence of hypertension, hyperlipidemia, diabetes mellitus and depression in men with erectile dysfunction","volume":"171","author":"Seftel","year":"2004","journal-title":"J Urol"},{"key":"2024032600473892200_bib7","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1159\/000065541","article-title":"Penile arteries and erection","volume":"39","author":"Simonsen","year":"2002","journal-title":"J Vasc Res"},{"key":"2024032600473892200_bib8","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.jad.2003.12.008","article-title":"A population study of the association between sexual function, sexual satisfaction and depressive symptoms in men","volume":"82","author":"Nicolosi","year":"2004","journal-title":"J Affect Disord"},{"key":"2024032600473892200_bib9","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/j.1743-6109.2005.20104_1.x","article-title":"Erectile dysfunction is a marker for cardiovascular disease: Results of the minority health institute expert advisory panel","volume":"2","author":"Billups","year":"2005","journal-title":"J Sex Med"},{"key":"2024032600473892200_bib10","article-title":"Management of erectile dysfunction","author":"American Urological Association","year":"2005"},{"key":"2024032600473892200_bib11","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1185\/030079904125003467","article-title":"The multinational Men\u2019s Attitudes to Life Events and Sexuality (MALES) study. I. Prevalence of erectile dysfunction and related health concerns in the general population","volume":"20","author":"Rosen","year":"2004","journal-title":"Curr Med Res Opin"},{"issue":"suppl 2","key":"2024032600473892200_bib12","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S1569-9056(03)80383-4","article-title":"Attitudes toward treatment of erectile dysfunction: Results from the MALES study","author":"Eardley","year":"2003","journal-title":"Eur Urol"},{"key":"2024032600473892200_bib13","doi-asserted-by":"crossref","first-page":"777","DOI":"10.2337\/diacare.26.3.777","article-title":"Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: A multicenter double-blind placebo-controlled fixed-dose study","volume":"26","author":"Goldstein","year":"2003","journal-title":"Diabetes Care"},{"key":"2024032600473892200_bib14","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0090-4295(03)00359-5","article-title":"Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: A randomized controlled trial","volume":"62","author":"Porst","year":"2003","journal-title":"Urology"},{"key":"2024032600473892200_bib15","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/S0022-5347(18)35044-4","article-title":"High prevalence of significant comorbid conditions in men with erectile dysfunction: Momentus trial demonstrates efficacy and safety of tadalafil in this group","volume":"173","author":"Goldstein","year":"2005","journal-title":"J Urol"},{"key":"2024032600473892200_bib16","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1111\/j.1743-6109.2004.04025.x","article-title":"Earliest time to onset of action leading to successful intercourse with vardenafil determined in an at-home setting: A randomized, double-blind, placebo-controlled trial","volume":"1","author":"Montorsi","year":"2004","journal-title":"J Sex Med"},{"key":"2024032600473892200_bib17","first-page":"2687","article-title":"Penetration and maintenance of erection with vardenafil: A time-from-dosing analysis","volume":"12","author":"Valiquette","year":"2005","journal-title":"Can J Urol"},{"key":"2024032600473892200_bib18","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1177\/147323000503300309","article-title":"The real-life safety and efficacy of vardenafil: An international post-marketing surveillance study\u2014Results from 29,358 German patients","volume":"33","author":"Van Ahlen","year":"2005","journal-title":"J Int Med Res"},{"key":"2024032600473892200_bib19","doi-asserted-by":"crossref","first-page":"259","DOI":"10.3122\/jabfm.11.4.259","article-title":"Barriers to recognition of erectile dysfunction among diabetic Mexican-American men","volume":"11","author":"Zweifler","year":"1998","journal-title":"J Am Board Fam Pract"},{"key":"2024032600473892200_bib20","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1111\/j.1743-6109.2005.00150.x","article-title":"Safety and efficacy of vardenafil, a selective phosphodiesterase 5 inhibitor, in patients with erectile dysfunction and arterial hypertension treated with multiple antihypertensives","volume":"2","author":"Van Ahlen","year":"2005","journal-title":"J Sex Med"},{"key":"2024032600473892200_bib21","doi-asserted-by":"crossref","first-page":"777","DOI":"10.2337\/diacare.26.3.777","article-title":"Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes","volume":"26","author":"Goldstein","year":"2003","journal-title":"Diabetes Care"},{"key":"2024032600473892200_bib22","first-page":"A127","article-title":"Efficacy and safety of vardenafil, a selective phosphodiesterase 5 inhibitor, in type 1 diabetic patients with erectile dysfunction","volume":"54","author":"Ziegler","year":"2005","journal-title":"Diabetes"},{"key":"2024032600473892200_bib23","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1743-6109.04043.x","article-title":"Vardenafil improves erectile function in men with erectile dysfunction irrespective of disease severity and disease classification","volume":"1","author":"Donatucci","year":"2004","journal-title":"J Sex Med"},{"key":"2024032600473892200_bib24","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1743-6109.2004.04027.x","article-title":"Vardenafil improves patient satisfaction with erection hardness, orgasmic function, and overall sexual experience, while improving quality of life in men with erectile dysfunction","volume":"1","author":"Donatucci","year":"2004","journal-title":"J Sex Med"},{"key":"2024032600473892200_bib25","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/j.1743-6109.2005.20111.x","article-title":"Vardenafil improves satisfaction rates, depressive symptomatology, and self-confidence in a broad population of men with erectile dysfunction","volume":"2","author":"Hatzichristou","year":"2005","journal-title":"J Sex Med"},{"issue":"suppl","key":"2024032600473892200_bib26","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/S0090-4295(02)01688-6","article-title":"Achieving treatment optimization with sildenafil citrate (Viagra) in patients with erectile dysfunction","volume":"60","author":"McCullough","year":"2002","journal-title":"Urology"},{"key":"2024032600473892200_bib27","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.urology.2004.05.046","article-title":"Integrated analysis examining first-dose success, success by dose, and maintenance of success among men taking tadalafil for erectile dysfunction","volume":"64","author":"Schulman","year":"2004","journal-title":"Urology"},{"key":"2024032600473892200_bib28","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/j.urology.2004.07.038","article-title":"Simultaneous administration of vardenafil and tamsulosin does not induce clinically significant hypotension in patients with benign prostatic hyperplasia","volume":"64","author":"Auerbach","year":"2004","journal-title":"Urology"},{"key":"2024032600473892200_bib29","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S0022-5347(18)35966-4","article-title":"Cardiovascular safety of the combination of vardenafil and alpha-blockers: A subgroup analysis of the post-marketing surveillance study \u2018real life safety and efficacy\u2019 of vardenafil (REALISE)","volume":"173","author":"Van Ahlen","year":"2005","journal-title":"J Urol"},{"key":"2024032600473892200_bib30","article-title":"Levitra\u00ae vardenafil HCl [package insert]","year":"2005"}],"container-title":["The Journal of Sexual Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1743609515315472?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1743609515315472?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/4\/2\/432\/47810314\/jsm_4_2_432.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/4\/2\/432\/47810314\/jsm_4_2_432.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,26]],"date-time":"2024-03-26T01:38:07Z","timestamp":1711417087000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jsm\/article\/4\/2\/432\/6890028"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,3,1]]},"references-count":30,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2007,3,1]]},"published-print":{"date-parts":[[2007,3,1]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1743-6109.2006.00383.x","relation":{},"ISSN":["1743-6109","1743-6095"],"issn-type":[{"value":"1743-6109","type":"electronic"},{"value":"1743-6095","type":"print"}],"subject":[],"published-other":{"date-parts":[[2007,3]]},"published":{"date-parts":[[2007,3,1]]}}}